These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 14672741)

  • 1. Mechanisms governing the accumulation of estrogen receptor alpha in MCF-7 breast cancer cells treated with hydroxytamoxifen and related antiestrogens.
    Laïos I; Journe F; Laurent G; Nonclercq D; Toillon RA; Seo HS; Leclercq G
    J Steroid Biochem Mol Biol; 2003 Nov; 87(2-3):207-21. PubMed ID: 14672741
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
    Marsaud V; Gougelet A; Maillard S; Renoir JM
    Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.
    El Khissiin A; Journé F; Laïos I; Seo HS; Leclercq G
    Steroids; 2000 Dec; 65(12):903-13. PubMed ID: 11077089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the proteasome in the regulation of estrogen receptor alpha turnover and function in MCF-7 breast carcinoma cells.
    Laïos I; Journé F; Nonclercq D; Vidal DS; Toillon RA; Laurent G; Leclercq G
    J Steroid Biochem Mol Biol; 2005 Mar; 94(4):347-59. PubMed ID: 15857754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physicochemical and genetic evidence for specific antiestrogen binding sites.
    Faye JC; Jozan S; Redeuilh G; Baulieu EE; Bayard F
    Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3158-62. PubMed ID: 6574477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen responsiveness of IBEP-2, a new human cell line derived from breast carcinoma.
    Journé F; Body JJ; Leclercq G; Nonclercq D; Laurent G
    Breast Cancer Res Treat; 2004 Jul; 86(1):39-53. PubMed ID: 15218360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium.
    Jensen J; Kitlen JW; Briand P; Labrie F; Lykkesfeldt AE
    J Steroid Biochem Mol Biol; 2003 Mar; 84(4):469-78. PubMed ID: 12732292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of two estrogen-responsive proteins by antiestrogens in R27, a tamoxifen-resistant clone of MCF7 cells.
    Vignon F; Lippman ME; Nawata H; Derocq D; Rochefort H
    Cancer Res; 1984 May; 44(5):2084-8. PubMed ID: 6713400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
    MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
    Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Functional implications of antiestrogen induction of quinone reductase: inhibition of estrogen-induced deoxyribonucleic acid damage.
    Bianco NR; Perry G; Smith MA; Templeton DJ; Montano MM
    Mol Endocrinol; 2003 Jul; 17(7):1344-55. PubMed ID: 12714703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The neuropeptide y y(1) receptor: a diagnostic marker? Expression in mcf-7 breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts.
    Memminger M; Keller M; Lopuch M; Pop N; Bernhardt G; von Angerer E; Buschauer A
    PLoS One; 2012; 7(12):e51032. PubMed ID: 23236424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogenic and antiestrogenic regulation of the half-life of covalently labeled estrogen receptor in MCF-7 breast cancer cells.
    Borrás M; Laios I; el Khissiin A; Seo HS; Lempereur F; Legros N; Leclercq G
    J Steroid Biochem Mol Biol; 1996 Feb; 57(3-4):203-13. PubMed ID: 8645630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Domains of estrogen receptor alpha (ERalpha) required for ERalpha/Sp1-mediated activation of GC-rich promoters by estrogens and antiestrogens in breast cancer cells.
    Kim K; Thu N; Saville B; Safe S
    Mol Endocrinol; 2003 May; 17(5):804-17. PubMed ID: 12576490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stabilization of MORC2 by estrogen and antiestrogens through GPER1- PRKACA-CMA pathway contributes to estrogen-induced proliferation and endocrine resistance of breast cancer cells.
    Yang F; Xie HY; Yang LF; Zhang L; Zhang FL; Liu HY; Li DQ; Shao ZM
    Autophagy; 2020 Jun; 16(6):1061-1076. PubMed ID: 32401166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiestrogenic properties of keoxifene, trans-4-hydroxytamoxifen, and ICI 164384, a new steroidal antiestrogen, in ZR-75-1 human breast cancer cells.
    Poulin R; Merand Y; Poirier D; Levesque C; Dufour JM; Labrie F
    Breast Cancer Res Treat; 1989 Oct; 14(1):65-76. PubMed ID: 2605344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.
    Glaeser M; Niederacher D; Djahansouzi S; Hanstein B; Dittrich R; Beckmann MW; Fasching PA; Ackermann S
    Anticancer Res; 2006; 26(1B):735-44. PubMed ID: 16739346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accumulation of a non-binding form of estrogen receptor in MCF-7 cells under hydroxytamoxifen treatment.
    Leclercq G; Legros N; Piccart MJ
    J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):545-52. PubMed ID: 1562525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha.
    Brockdorff BL; Heiberg I; Lykkesfeldt AE
    Endocr Relat Cancer; 2003 Dec; 10(4):579-90. PubMed ID: 14713268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.